Study of Growth Hormone and Bone in Obesity
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Obesity Weight Loss, Osteoporosis, Gastrointestinal |
| Therapuetic Areas: | Endocrinology, Gastroenterology, Rheumatology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 1/17/2019 |
| Start Date: | August 2013 |
| End Date: | April 30, 2019 |
Skeletal Physiology Dysregulation in Obesity: The Role of Growth Hormone
Obesity is an important risk factor for osteoporosis and fractures. With the growing
prevalence of obesity in the U.S., understanding the pathophysiology of bone loss in this
population is of importance to public health. Growth hormone (GH) is a critical mediator of
bone homeostasis and is markedly reduced in obesity. Our preliminary data suggest an
important role for the GH/insulin-like growth factor 1 (IGF-1) system in the pathogenesis of
bone loss in obesity. The development of novel imaging techniques provides an opportunity to
investigate the effects of GH on skeletal structure and strength, which will provide insights
into the pathogenesis of obesity related bone loss. Understanding the pathophysiology of bone
loss in obesity may help identify new treatment targets for this important complication. The
investigator hypothesizes that low-dose GH administration for 18 months will improve skeletal
health.
prevalence of obesity in the U.S., understanding the pathophysiology of bone loss in this
population is of importance to public health. Growth hormone (GH) is a critical mediator of
bone homeostasis and is markedly reduced in obesity. Our preliminary data suggest an
important role for the GH/insulin-like growth factor 1 (IGF-1) system in the pathogenesis of
bone loss in obesity. The development of novel imaging techniques provides an opportunity to
investigate the effects of GH on skeletal structure and strength, which will provide insights
into the pathogenesis of obesity related bone loss. Understanding the pathophysiology of bone
loss in obesity may help identify new treatment targets for this important complication. The
investigator hypothesizes that low-dose GH administration for 18 months will improve skeletal
health.
Inclusion Criteria:
- Ages 18-65 and generally healthy
- BMI ≥ 25 kg/m2
- Bone mineral density (BMD) T score ≤ -1.0 and > -2.5 (as measured by DXA)
Exclusion Criteria:
- For women: amenorrhea for 3 months, pregnancy or breastfeeding, polycystic ovary
syndrome
- History of diabetes mellitus, cancer or other serious chronic disease
- Use of osteoporosis medications
- Anemia
We found this trial at
1
site
185 Cambridge Street
Boston, Massachusetts 02114
Boston, Massachusetts 02114
617-724-5200
Phone: 617-724-1837
Click here to add this to my saved trials
